## EXAS: Exact Sciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.2% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 87 overbought. Stock is in no-man's land without clear edge. Caution: declining volume (41% of avg), momentum weakening (-4.9% MRS), overbought RSI (87).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($99.20)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-28 | Stifel | $105 | $80 | +31% |
| 2025-11-25 | Canaccord Genui | $105 | $85 | +24% |
| 2025-11-24 | Benchmark | $0 | $0 | 0% |
| 2025-11-24 | Jefferies | $105 | $90 | +17% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-28 | Stifel | down | Hold |
| 2025-11-25 | Canaccord Genui | down | Hold |
| 2025-11-24 | Benchmark | down | Hold |
| 2025-11-24 | Jefferies | down | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 7 ($1.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- FMR, LLC: 9.8% (-30.6%)
- Vanguard Group Inc: 9.4% (-0.5%)
- Capital World Invest: 8.5% (-11.3%)
- Blackrock Inc.: 5.6% (+0.3%)
- Wellington Managemen: 2.8% (-55.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.9% 5d) with bearish MACD, trend may be turning.
2. Overbought RSI (87) with bearish MACD signals exhaustion.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 5 raises (avg +26%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Forward P/E 91.1x attractive for 231% earnings growth. Balance sheet: strong liquidity (2.7x). Analyst sentiment positive (5 raises, avg +26%). Insider selling cluster ($1.7M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.3B |
| Beta | 1.42 |
| 52W Range | $38.81 - $101.95 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.07 |
| Forward P/E | 91.1 |
| Current P/E | 301.1 |
| YoY Growth | 230.6% |
| EPS Direction | FALLING |

### Technicals

MRS_20 deteriorating from 5.0% to 0.2% (-4.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.8pp (needs >4.0% for momentum thesis). MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.32), momentum weakening. RSI overbought at 87, risk of mean reversion. Volume at 41% of 20MA suggests lack of conviction. OFD pattern: +MLN (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.17% (CS: 54) | Neutral |
| RSI_14 | 87.4 | Overbought |
| MACD Histogram | -1.32 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.265x | Above |
| vs SMA200 | 1.764x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $101.82
- **Stop Loss:** $99.20 (2.6% risk)
- **Target:** $104.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 458
- **Position Value:** $46,633.56
- **Portfolio %:** 46.63%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-25 (Est: $0.08)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.16 | $0.24 | +49.5% |
| 2025Q2 | $0.05 | $0.10 | +84.9% |
| 2025Q1 | $-0.10 | $-0.36 | -276.9% |
| 2024Q4 | $-0.19 | $-0.06 | +67.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*